Treatment with the glycogen synthase kinase-3/β inhibitor, TDZD-8, affects transient cerebral ischemia/reperfusion injury in the rat hippocampus

Shock

Volumn 30, Issue 3, 2008, Pages 299-307

  Collino, Massimo ^a   Thiemermann, Christoph ^b   Mastrocola, Raffaella ^a   Gallicchio, Margherita ^a   Benetti, Elisa ^a   Miglio, Gianluca ^a   Castiglia, Sara ^a   Danni, Oliviero ^a   Murch, Oliver ^a,b   Dianzani, Chiara ^a   Aragno, Manuela ^a   Fantozzi, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Apoptosis; beta; ; GSK 3; Hippocampus; I R; Inflammation; Oxidative stress; TDZD 8

Indexed keywords

4 BENZYL 2 METHYL 1,2,4 THIADIAZOLIDINE 3,5 DIONE; CASPASE 9; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; CYTOCHROME C; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN S100B; REACTIVE OXYGEN METABOLITE; SERINE; SUPEROXIDE DISMUTASE; TDZD 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN INFARCTION SIZE; BRAIN INJURY; CELL DAMAGE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; IN VIVO STUDY; INFLAMMATION; MALE; MITOCHONDRION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ANTIOXIDANTS; BRAIN; BRAIN ISCHEMIA; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MALE; MITOCHONDRIA; MODELS, BIOLOGICAL; NERVE GROWTH FACTORS; PHOSPHORYLATION; RATS; RATS, WISTAR; REPERFUSION INJURY; S100 PROTEINS; THIADIAZOLES;

EID: 52649101373     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318164e762     Document Type: Article

References (35)

1. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519-527, 1980.
2. Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 3:479-487, 2004.
3. Leroy K, Brion JP: Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanat 16:279-293, 1999.
4. Woodgett JR, Ohashi PS: GSK3: an in-Toll-erant protein kinase? Nat Immunol 6:751-752, 2005.
5. Nonaka S, Chuang DM: Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats. Neuroreport 9:2081-2084, 1998.
6. Kelly S, Zhao H, Hua Sun G, Cheng D, Qiao Y, Luo J, Martin K, Steinberg GK, Harrison SD, Yenari MA: Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia. Exp Neurol 188:378-386, 2004.
7. Sharma BK, Kumar K: Role of proinflammatory cytokines in cerebral ischemia: a review. Metab Brain Dis 13:1-8, 1998.
8. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadia-zolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 45:1292-1299, 2002.
9. Cuzzocrea S, Genovese T, Mazzon E, Crisafulli C, Di Paola R, Muia C, Collin M, Esposito E, Bramanti P, Thiemermann C: Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 318:79-89, 2006.
10. Dugo L, Abdelrahman M, Murch O, Mazzon E, Cuzzocrea S, Thiemermann C: Glycogen synthase kinase-3beta inhibitors protect against the organ injury and dysfunction caused by hemorrhage and resuscitation. Shock 25:485-491, 2006.
11. Dugo L, Collin M, Allen DA, Murch O, Foster SJ, Yaqoob MM, Thiemermann C: Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3beta inhibition. Crit Care Med 34:1489-1496, 2006.
12. Whittle BJ, Varga C, Posa A, Molnar A, Collin M, Thiemermann C: Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 147:575-582, 2006.
13. Cuzzocrea S, Mazzon E, Esposito E, Muia C, Abdelrahman M, Di Paola R, Crisafulli C, Bramanti P, Thiemermann C: Glycogen synthase kinase-3beta inhibition attenuates the development of ischaemia/reperfusion injury of the gut. Intensive Care Med 33:880-893, 2007.
14. Schaller B: Prospects for the future: the role of free radicals in the treatment of stroke. Free Radic Biol Med 38:411-425, 2005.
15. Del Zoppo GJ: Stroke and neurovascular protection. N Engl J Med 354: 553-555, 2006.
16. Ferrer I: Apoptosis: future targets for neuroprotective strategies. Cerebrovasc Dis 21(suppl 2):9-20, 2006.
17. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R: Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med 41:579-589, 2006.
18. Swanson RA, Morion MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR: A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10:290-293, 1990.
19. Meldrum DR, Shenkar R, Sheridan BC, Cain BS, Abraham E, Harken AH: Hemorrhage activates myocardial NFkappaB and increases TNF-alpha in the heart. J Mol Cell Cardiol 29:2849-2854, 1997.
20. Perez-Pinzon MA, Xu GP, Born J, Lorenzo J, Busto R, Rosenthal M, Sick TJ: Cytochrome C is released from mitochondria into the cytosol after cerebral anoxia or ischemia. J Cereb Blood Flow Metab 19:39 - 43, 1999.
21. Shaw M, Cohen P, Alessi DR: Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416:307-311, 1997.
22. Eklof B, Siesjo BK: The effect of bilateral carotid artery ligation upon the blood flow and the energy state of the rat brain. Acta Physiol Scand 86: 155-165, 1972.
23. Vanella A, Sorrenti V, Gambera G, Castorina C, Di Giacomo C, Campisi A, Salva M, Perez-Polo JR: Lipid peroxidation in rat cerebral cortex during post-ischemic reperfusion: effect of exogenous antioxidants and Ca(++)-antagonist drugs. Ital J Biochem 39:196-198, 1990.
24. Heizmann CW, Fritz G, Schafer BW: S100 proteins: structure, functions and pathology. Front Biosci 7:1356-1368, 2002.
25. Buyukuysal RL: Protein S100B release from rat brain slices during and after ischemia: comparison with lactate dehydrogenase leakage. Neurochem Int 47:580-588, 2005.
26. Frame S, Zheleva D: Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets 10:429-444, 2006.
27. Homola A, Zoremba N, Slais K, Kuhlen R, Sykova E: Changes in diffusion parameters, energy-related metabolites and glutamate in the rat cortex after transient hypoxia/ischemia. Neurosci Lett 404:137-142, 2006.
28. Schafer M, Goodenough S, Moosmann B, Behl C: Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 1005:84-89, 2004.
29. Watcharasit P, Thiantanawat A, Satayavivad J: GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption. J Appl Toxicol 2007 Sep 12; [Epub ahead of print].
30. Takashima A, Honda T, Yasutake K, Michel G, Murayama O, Murayama M, Ishiguro K, Yamaguchi H: Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31:317-323, 1998.
31. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86-90, 2000.
32. Takada Y, Fang X, Jamaluddin MS, Boyd DD, Aggarwal BB: Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J Biol Chem 279:39541-39554, 2004.
33. Shen WH, Zhang CY, Zhang GY: Antioxidants attenuate reperfusion injury after global brain ischemia through inhibiting nuclear factor-kappa B activity in rats. Acta Pharmacol Sin 24:1125-1130, 2003.
34. Carter AB, Knudtson KL, Monick MM, Hunninghake GW: The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem 274: 30858-30863, 1999.
35. Pagel PS, Krolikowski JG, Neff DA, Weihrauch D, Bienengraeber M, Kersten JR, Warltier DC: Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth Analg 102:1348-1354, 2006.